What question did this study set out to answer?

To evaluate the effectiveness of adalimumab in treating refractory sweet's syndrome in a patient with myelodysplastic syndrome.

January 25, 2026eJHaem0 citationsOpen Access

Successful Treatment of Refractory Sweet's Syndrome With Adalimumab in a Myelodysplastic Syndrome Patient

View Full Paper

LMLiya Ma YSYaojia Shen JCJie Chang

Key Points

To evaluate the effectiveness of adalimumab in treating refractory sweet's syndrome in a patient with myelodysplastic syndrome.
Case report of a 69-year-old male patient
Administered azacitidine and selinexor for myelodysplastic syndrome
Diagnosed with sweet's syndrome via skin biopsy
Treated with adalimumab for skin lesions
Resolvation of sweet's syndrome symptoms after adalimumab treatment
Occurrence of secondary disseminated fungal infections
Patient ultimately died from heart failure and severe infection

Abstract

ABSTRACT We report a 69‐year‐old man diagnosed as myelodysplastic syndrome and administrated with azacitidine and selinexor treatment. Then he was revealed high fever and multiple tender erythematous papules involving his mouth, back, upper and lower extremities, which were diagnosed as Sweet's syndrome by skin biopsy. He was administrated with adalimumab and his rashes gradually disappeared after adalimumab treatment. But he had secondary disseminated fungal infections. Finally, he died of heart failure and severe infection. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Ma et al. (Thu,) studied this question.

synapsesocial.com/papers/6975b1eafeba4585c2d6d5c6 https://doi.org/https://doi.org/10.1002/jha2.70218

Perguntar à IA

Bookmark

View Full Paper